However, some of these uncommon mutations, such as exon 18 G719X or exon 20 S768I, do not have a negligible frequency (approximately 1–2% of all non-squamous NSCLCs), comparable to that of other rare oncogene-addicted NSCLC subgroups, such as RET (rearranged during transfection) or ROS1 (c-ros oncogene 1) rearrangements or BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations [26,27,28], which are under active clinical development. This evidence concerns the gene BRAF and non-small cell lung carcinoma.